Responsive and monophasic lupus nephritis: prevalence, associations and outcomes.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40198238.
- Also identified by DOI 10.1093/rheumatology/keaf187.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
LN is associated with significant renal morbidity, although some patients may experience a responsive and monophasic course. We aimed to assess the proportion of LN patients with such a course and identify its associated baseline characteristics. This retrospective study included SLE patients from an observational cohort who developed LN at or after clinic entry. A responsive and monophasic course was defined as complete proteinuria recovery within 1 year for subnephrotic- or 2 years for nephrotic-range proteinuria, without subsequent renal flares. Univariable and multivariable logistic regression were used to assess the impact of baseline characteristics on developing a responsive and monophasic course, while Cox regression was used to explore the association with a long-term adverse composite outcome, including end-stage kidney disease, sustained ≥30% estimated glomerular filtration rate (eGFR) decline, or death. Among 374 LN patients (mean age: 32.8 years; 89.2% female; median follow-up: 10.6 years), 96 patients (25.7%) exhibited a responsive and monophasic course, which was associated with older age [odds ratio (OR) 1.04, 95% CI 1.01-1.07] and shorter SLE duration (OR 0.91, 95% CI 0.86-0.97) at LN onset. In the Cox model, timely recovery of proteinuria and the absence of subsequent LN flares were associated with a reduced risk of the adverse composite outcome. Despite these associations, 18.8% of patients with a responsive and monophasic course still experienced adverse events. Approximately 26% of LN patients exhibit a responsive and monophasic course. Predicting such a course remains challenging; despite improved outcomes, 18.8% of these patients still experience adverse long-term events.
Medical subject headings
- Lupus Nephritis